Quality Improvement High-Sensitivity Cardiac Troponin I vs a Clinical Chemistry Score for Predicting All-Cause Mortality in an Emergency Department Population

被引:5
|
作者
Kavsak, Peter A. [1 ,6 ]
Cerasuolo, Joshua O. [2 ]
Ko, Dennis T. [3 ]
Ma, Jinhui [4 ]
Sherbino, Jonathan [5 ]
Mondoux, Shawn E. [5 ]
Perez, Richard [2 ]
Seow, Hsien [2 ]
Worster, Andrew [5 ]
机构
[1] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada
[2] McMaster Univ, Fac Hlth Sci, ICES McMaster, Hamilton, ON, Canada
[3] ICES, Toronto, ON, Canada
[4] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada
[5] McMaster Univ, Div Emergency Med, Hamilton, ON, Canada
[6] Juravinski Hosp & Canc Ctr, 711 Concess St, Hamilton, ON L8V 1C3, Canada
基金
加拿大健康研究院;
关键词
MYOCARDIAL-INFARCTION; RISK STRATIFICATION; EUROPEAN-SOCIETY; ALGORITHMS; OUTCOMES; DEATH;
D O I
10.1016/j.cjco.2020.03.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: For patients investigated for suspected acute coronary syndrome, there is uncertainty if a single measurement of high -sensitivity cardiac troponin I (hs-cTnI) at emergency department (ED) presentation can identify patients at both low and high risk for mortality.Methods: We included consecutive adult patients in the ED who had a Clinical Chemistry Score (CCS) taken at presentation (ie, combination of glucose, creatinine for estimated glomerular filtration rate deter-mination, and hs-cTnI assay) in a Canadian city between 2012 and 2013. Outcomes were 3-month, 1-year, and 5-year all-cause mortality using the provincial death registry. Mortality rates and test perfor-mance (eg, sensitivity and specificity) with 95% confidence intervals (CIs) were obtained for the CCS or hs-cTnI assay alone using estab-lished cutoffs for these tests.Results: Our cohort included 5974 patients with a 1-year mortality rate of 17.2% (95% CI, 16.2-18.3). A CCS > 1 yielded a sensitivity of 99.2% (95% CI, 98.4-99.6) compared with the hs-cTnI > 5 ng/L cutoff sensitivity of 88.4% (95% CI, 86.3-90.3), with the mortality rate being significantly lower for patients with CCS < 1 (2.0%; 95% CI, 0.9-4.0) vs patients with hs-cTnI < 5 ng/L (5.0%; 95% CI, 4.2-6.0) at 1 year (P = 0.01). A CCS of 5 also yielded a higher specificity (88.5%; 95% CI, 87.5-89.3) compared with hs-cTnI > 26 ng/L (83.9%; 95% CI, 82.9-84.9), with no difference in mortality rates (37.4% vs 36.3%; P = 0.66). This trend was consistent at 3-month and 5-year mortality. Conclusion: For patients in the ED with a potential cardiac issue, using the CCS cutoffs can better identify patients at low and high risk for mortality than using published cutoffs for hs-cTnI alone.
引用
收藏
页码:296 / 302
页数:7
相关论文
共 50 条
  • [1] High-Sensitivity Cardiac Troponin I for Predicting Death in a Female Emergency Department Population
    Kavsak, Peter A.
    Shortt, Colleen
    Pond, Greg
    Worster, Andrew
    CLINICAL CHEMISTRY, 2014, 60 (01) : 271 - 273
  • [2] Measurement of cardiac troponin I levels in the emergency department: predictive value for cardiac and all-cause mortality
    Wilcox, G
    Archer, PD
    Bailey, M
    Dziukas, L
    Lim, CF
    Schneider, HG
    MEDICAL JOURNAL OF AUSTRALIA, 2001, 174 (04) : 170 - 173
  • [3] Association Between All-Cause Mortality and High-Sensitivity Cardiac Troponin Concentrations in Patients With Chest Pain
    Annie, Frank H.
    Kepfinger, Joshua
    Ahmed, Fatima
    Pervez, Muhammad Ijaz
    Elashery, Ahmad
    ANGIOLOGY, 2024, 75 (08) : 772 - 778
  • [4] High-sensitivity troponin I predicts all-cause mortality in stable COPD in the COSYCONET cohort study
    Waschki, Benjamin
    Alter, Peter
    Zeller, Tanja
    Magnussen, Christina
    Neumann, Johannes
    Herr, Christian
    Blankenberg, Stefan
    Rabe, Klaus
    Welte, Tobias
    Joerres, Rudolf A.
    Vogelmeier, Claus Franz
    Bals, Robert
    Watz, Henrik
    INTERNIST, 2019, 60 : S50 - S50
  • [5] High-sensitivity troponin I and all-cause mortality in patients with stable COPD: an analysis of the COSYCONET study
    Waschki, Benjamin
    Alter, Peter
    Zeller, Tanja
    Magnussen, Christina
    Neumann, Johannes T.
    Twerenbold, Raphael
    Sinning, Christoph
    Herr, Christian
    Kahnert, Kathrin
    Faehndrich, Sebastian
    Blankenberg, Stefan
    Rabe, Klaus F.
    Welte, Tobias
    Joerres, Rudolf A.
    Vogelmeier, Claus F.
    Bals, Robert
    Watz, Henrik
    EUROPEAN RESPIRATORY JOURNAL, 2020, 55 (02)
  • [6] The Relationship of Sudden Death and All-cause Mortality to Baseline Values of High-sensitivity Cardiac Troponin T and I in the EVOLVE Trial
    Herzog, Charles A.
    Tsirtsonis, Kate
    Apple, Fred S.
    CIRCULATION, 2017, 136
  • [7] The Role of High-Sensitivity Cardiac Troponin I in the Predicting Long-Term Clinical Outcome of Patients With Malignancy at Emergency Department
    Park, Soo Hyun
    Kim, Taerim
    Song, Keun Jeong
    Sim, Min Sub
    Jeong, Yeon Kwon
    Jo, Ik Joon
    Shin, Tae Gun
    Cha, Won Chul
    Yoon, Hee
    Hwang, Sung Yeon
    Choi, Jin-Ho
    Lee, Seung-Hwa
    Song, Minseok
    Kang, Eun-Jin
    Park, Joo Hyun
    Lee, Gun Tak
    Park, Jongen
    CIRCULATION, 2019, 140
  • [8] Admission High-Sensitivity Cardiac Troponin vs a Biochemical Score for Predicting Mortality in Patients With COVID-19
    Kavsak, Peter A.
    Mondoux, Shawn E.
    de Wit, Kerstin
    Rochwerg, Bram
    Main, Cheryl
    Yamamura, Deborah
    Pare, Guillaume
    Ma, Jinhui
    Perri, Dan
    Sherbino, Jonathan
    Worster, Andrew
    CJC OPEN, 2021, 3 (01) : 130 - 131
  • [9] Clinical Performance Evaluation of the Atellica IM High-Sensitivity Troponin I Assay to Aid in Risk Stratification for All-Cause Mortality and Major Adverse Cardiac Events
    Kampfrath, T.
    Bethoney, S.
    Snyder, J.
    Zhang, J.
    Butterfield, R.
    CLINICAL CHEMISTRY, 2024, 70
  • [10] Emergency Department Cardiac Risk Stratification With High-Sensitivity vs Conventional Troponin HEART Pathway
    Yore, Mackensie
    Sharp, Adam
    Wu, Yi-Lin
    Kawatkar, Aniket
    Lee, Ming-Sum
    Ferencik, Maros
    Redberg, Rita
    Shen, Ernest
    Zheng, Chengyi
    Sun, Benjamin
    JAMA NETWORK OPEN, 2023, 6 (12) : E2348351